HuGE Literature Finder
Records
1
-
15
| Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02). Thoracic cancer 2022 4 13 (10): 1471-1478. Tanaka Hisashi, Sakamoto Hiroaki, Akita Takahiro, Ohyanagi Fumiyoshi, Kawashima Yosuke, Tambo Yuichi, Tanimoto Azusa, Horiike Atsushi, Miyauchi Eisaku, Tsuchiya-Kawano Yuko, Yanagitani Noriko, Nishio Mako |
| A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Cancer medicine 2021 Sep . Lee Ji Hyun, Heo Seong Gu, Ahn Beung-Chul, Hong Min Hee, Cho Byoung Chul, Lim Sun Min, Kim Hye Ry |
| Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. Clinical colorectal cancer 2021 Jul . Alshammari Kanan, Aung Kyaw L, Zhang Tong, Razak Albiruni R A, Serra Stefano, Stockley Tracy, Wang Lisa, Nguyen Jessica, Spreafico Anna, Hansen Aaron R, Zwir Dave, Siu Lillian L, Bedard Philippe |
| Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence. Journal of oncology 2021 12 2021 8736288. Zhang Lemeng, Luo Yongzhong, Chen Jianhua, Cheng Tianli, Yang Hua, Pan Changqie, Li Haitao, Jiang Zh |
| A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. Lung cancer (Amsterdam, Netherlands) 2019 7 134 46-51. Park Ji Soo, Hong Min Hee, Chun You Jin, Kim Hye Ryun, Cho Byoung Ch |
| A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 10 15 (1): 80-90. Scagliotti Giorgio, Moro-Sibilot Denis, Kollmeier Jens, Favaretto Adolfo, Cho Eun Kyung, Grosch Heidrun, Kimmich Martin, Girard Nicolas, Tsai Chun-Ming, Hsia Te-Chun, Brighenti Matteo, Schumann Christian, Wang Xuejing Aimee, Wijayawardana Sameera R, Gruver Aaron M, Wallin Johan, Mansouri Kambiz, Wacheck Volker, Chang Gee-Ch |
| Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. BMC cancer 2018 Dec 18 (1): 1231. Tsutani Yasuhiro, Miyata Yoshihiro, Masuda Takeshi, Fujitaka Kazunori, Doi Mihoko, Awaya Yoshikazu, Kuyama Shoichi, Kitaguchi Soichi, Ueda Kazuhiro, Hattori Noboru, Okada Morihi |
| Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma. Clinical lung cancer 2018 8 19 (5): e775-e781. Oh In-Jae, Hur Jae Young, Park Cheol-Kyu, Kim Young-Chul, Kim Seung Joon, Lee Min Ki, Kim Hee Joung, Lee Kye Young, Lee Jae Cheol, Choi Chang-M |
| A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. Oncotarget 2017 Sep 8 (41): 69651-69662. Leighl Natasha B, Tsao Ming-Sound, Liu Geoffrey, Tu Dongsheng, Ho Cheryl, Shepherd Frances A, Murray Nevin, Goffin John R, Nicholas Garth, Sakashita Shingo, Chen Zhuo, Kim Lucia, Powers Jean, Seymour Lesley, Goss Glenwood, Bradbury Penelope |
| [The therapeutic value and safety of icotinib as first-line therapy for advanced non-small cell lung cancer patients]. Zhonghua nei ke za zhi 2017 Jan 56 (1): 39-43. Chen H, Wang H P, Zhang L, Si X |
| Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer. Oncotarget 2016 Nov . Zhang Tongtong, Li Qing, Chen Shanshan, Luo Yang, Fan Ying, Xu Bing |
| Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer. Anticancer research 2016 Sep 36 (9): 4951-4. Inomata Minehiko, Shimokawa Kazuki, Tokui Kotaro, Taka Chihiro, Okazawa Seisuke, Kambara Kenta, Yamada Toru, Miwa Toshiro, Hayashi Ryuji, Kashii Tatsuhiko, Matsui Shoko, Tobe Kazuyu |
| Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Annals of oncology : official journal of the European Society for Medical Oncology 2016 Mar 27 (3): 423-9. Ramalingam S S, O'Byrne K, Boyer M, Mok T, Jänne P A, Zhang H, Liang J, Taylor I, Sbar E I, Paz-Ares |
| Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Apr 21 (7): 1583-90. Bohanes Pierre, Rankin Cathryn J, Blanke Charles D, Winder Thomas, Ulrich Cornelia M, Smalley Stephen R, Rich Tyvin A, Martensen James A, Benson Al B, Mayer Robert J, Cripps Christine M, Danenberg Kathleen, Makar Karen W, Zhang Wu, Benedetti Jacqueline K, Lenz Heinz-Jos |
| Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet. Oncology 2015 Feb 16 (2): 141-51. Yang James Chih-Hsin, Wu Yi-Long, Schuler Martin, Sebastian Martin, Popat Sanjay, Yamamoto Nobuyuki, Zhou Caicun, Hu Cheng-Ping, O'Byrne Kenneth, Feng Jifeng, Lu Shun, Huang Yunchao, Geater Sarayut L, Lee Kye Young, Tsai Chun-Ming, Gorbunova Vera, Hirsh Vera, Bennouna Jaafar, Orlov Sergey, Mok Tony, Boyer Michael, Su Wu-Chou, Lee Ki Hyeong, Kato Terufumi, Massey Dan, Shahidi Mehdi, Zazulina Victoria, Sequist Lecia |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 28, 2023
- Content source: